Page last updated: 2024-12-07

bismuth nitrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID107711
MeSH IDM0180212

Synonyms (22)

Synonym
ccris 7110
einecs 233-791-8
nitric acid, bismuth(3+) salt
bismuth nitrate
bismuth trinitrate
nitric acid, bismuth(3+) salt (3:1)
10361-44-1
4r459r54n0 ,
unii-4r459r54n0
ec 233-791-8
AKOS015915832
46140-16-3
PPNKDDZCLDMRHS-UHFFFAOYSA-N
tris(nitrooxy)bismuthine
nitric acid bismuth(3+) salt (3:1)
bismuth nitrate [mi]
bismuth,tris(nitrato-o,o')-, (oc-6-11)- (9ci)
FT-0725800
DTXSID30883121
bismuth;trinitrate
dinitrooxybismuthanyl nitrate
bismuth,tris(nitrato-o,o')-,(oc-6-11)-(9ci)

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with bismuth nitrate depressed the renal toxicity of CDDP without compromising its activity against a transplantable human bladder tumor."( Effect of bismuth nitrate given in combination with cis-diamminedichloroplatinum(II) on the antitumor activity and renal toxicity of the latter in nude mice inoculated with human bladder tumor.
Akimoto, M; Imura, N; Kondo, Y; Satoh, M, 1991
)
1.01

Toxicity

ExcerptReferenceRelevance
"The kidney, in particular the proximal convoluted tubule, is a major target site for the toxic effects of various metals."( Exposure of cultured human proximal tubular cells to cadmium, mercury, zinc and bismuth: toxicity and metallothionein induction.
Hawksworth, GM; Jenner, W; Miles, AT; Rodilla, V, 1998
)
0.3
" Safety and tolerability were assessed by adverse events, physical examination and serum biochemistry."( Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects.
Chen, A; Jiang, N; Meng, L; Ou, N; Shi, R; Tang, N; Wang, Y; Wu, D; Xu, K; Zhang, H; Zhang, P; Zhang, X, 2012
)
0.38
"In both the single- and multiple-dose studies, no severe adverse events were observed in any of the volunteers."( Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects.
Chen, A; Jiang, N; Meng, L; Ou, N; Shi, R; Tang, N; Wang, Y; Wu, D; Xu, K; Zhang, H; Zhang, P; Zhang, X, 2012
)
0.38
"Bismuthyl ecabet was shown to be safe and well tolerated in healthy Chinese subjects."( Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects.
Chen, A; Jiang, N; Meng, L; Ou, N; Shi, R; Tang, N; Wang, Y; Wu, D; Xu, K; Zhang, H; Zhang, P; Zhang, X, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" In addition, the incidence of micronucleus induction seemed to be reduced by double dosing with K2CrO4 and H2SeO3, compared to single dosing."( Micronucleus induction by chromium and selenium, and suppression by metallothionein inducer.
Itoh, S; Shimada, H, 1996
)
0.29
" The oral dosing regimen selected for subsequent phase II/III clinical trials was 800 mg twice daily."( Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects.
Chen, A; Jiang, N; Meng, L; Ou, N; Shi, R; Tang, N; Wang, Y; Wu, D; Xu, K; Zhang, H; Zhang, P; Zhang, X, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (6.82)18.7374
1990's17 (38.64)18.2507
2000's6 (13.64)29.6817
2010's13 (29.55)24.3611
2020's5 (11.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.82 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index99.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (6.67%)5.53%
Reviews2 (4.44%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]